Bristol-Myers Squibb has won FDA approval to market dasatinib for certain forms of leukemia. BMS won accelerated approval of the drug--to be marketed as Sprycel--from the agency for all phases of chronic myeloid leukemia in patients resistant to Gleevec. The FDA also approved the drug for patients resistant to therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia.
- here's the AP report on the approval